Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at pcp week 36
Awards & highlights
Study Summary
This study is evaluating whether a drug called GB004 may help people with ulcerative colitis.
Eligible Conditions
- Ulcerative Colitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at pcp week 36
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at pcp week 36
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Participants With Clinical Remission at PCP Week 12
Percentage of Participants With a Treatment Emergent Adverse Event
Secondary outcome measures
Percentage of Participants With Clinical Remission at PCP Week 36
Percentage of Participants With Clinical Response at PCP Week 12
Percentage of Participants With Clinical Response at PCP Week 36
+6 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: PCP GB004 480 mg QDExperimental Treatment1 Intervention
PCP GB004 480 mg QD for oral administration for 36 weeks
Group II: PCP GB004 480 mg BIDExperimental Treatment1 Intervention
PCP GB004 480 mg BID for oral administration for 36 weeks
Group III: Open-Label Extension (OLE) GB004 480 mg BIDExperimental Treatment1 Intervention
OLE GB004 480 mg BID for oral administration for 24 weeks
Group IV: PCP PlaceboPlacebo Group1 Intervention
PCP Placebo for oral administration for 36 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GB004
2019
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
GB004, Inc.Lead Sponsor
Barrett Levesque, MDStudy DirectorGossamer Bio Inc.
Share this study with friends
Copy Link
Messenger